Moderna Inc. ($MRNA) Stock Forecast: Up 5.2% Today

What is Moderna Inc.?

Moderna (MRNA) is a leading biotechnology company recognized for its cutting-edge mRNA technology, especially in the realm of vaccine creation. The company has played a pivotal role in combatting the COVID-19 pandemic with its successful mRNA-based vaccine.

Why is Moderna Inc. going up?

MRNA stock is up 5.2% on Mar 2, 2026 16:40

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot

Moderna's stock rose after the EMA’s CHMP recommended marketing authorization for its COVID-19 and influenza combination vaccine, mCombriax. This recommendation, supported by positive Phase III study data, is a significant step towards approval in the EU. The company is also pursuing regulatory approvals in other regions, despite previous challenges with the FDA regarding its flu vaccine component.

https://www.tradingview.com/news/zacks:135fc76a8094b:0-mrna-stock-gains-after-chmp-endorses-covid-19-influenza-combo-shot/

Moderna Stock (MRNA) Opinions on Piper Sandler Price Target Hike

Piper Sandler recently raised its price target for Moderna (MRNA) to $69, maintaining an Overweight rating due to a strong vaccine pipeline. Key drivers include an August PDUFA date for the flu shot and upcoming Phase III melanoma data, alongside pipeline advancements such as a new cancer vaccine factory and EMA approval for a flu-COVID combo shot. While growth prospects are highlighted, discussions also acknowledge lingering safety concerns regarding mRNA technology from recent studies.

https://www.quiverquant.com/news/Moderna+Stock+%28MRNA%29+Opinions+on+Piper+Sandler+Price+Target+Hike

Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze?

Annovis Bio, a clinical-stage biotech, is generating significant investor interest due to recent updates on its Alzheimer's and Parkinson's programs. The company's lead candidate, buntanetap, aims to target neurotoxic proteins, and its progress is closely watched by investors given the high-risk, high-upside nature of the stock. Key factors influencing its performance include clinical trial data, funding, and the potential for a short squeeze if positive data emerges.

https://www.ad-hoc-news.de/boerse/news/ueberblick/annovis-bio-stock-can-fresh-alzheimer-s-data-spark-the-next-big-short/68622608

FDA Draft Guidance Puts CRISPR Therapeutics Gene Editing Outlook In Focus

The FDA has issued new draft guidance aimed at expediting approvals for gene editing and RNA-based therapies, directly impacting companies like CRISPR Therapeutics and its CASGEVY program. This guidance introduces master protocols that could allow for evaluating multiple gene editing products within a single trial, potentially streamlining the regulatory process for future treatments. While this could be a significant positive for CRISPR Therapeutics, especially given its focus on rare diseases and its partnership with Vertex Pharmaceuticals, investors are also advised to consider the company's current unprofitability and early-stage pipeline risks.

https://www.sahmcapital.com/news/content/fda-draft-guidance-puts-crispr-therapeutics-gene-editing-outlook-in-focus-2026-02-27

Alnylam Phase 1 ALN-4285 Data Highlights Expanding RNAi Platform Potential

Alnylam Pharmaceuticals reported preliminary safety and pharmacokinetic data from its Phase 1 clinical study of ALN-4285, an RNA-based drug targeting a novel disease-related protein. This early data is significant as it demonstrates the versatility of Alnylam's RNA platform in targeting new diseases, contributing to the broader pipeline potential. While it won't impact near-term revenue, successful progression of ALN-4285 could strengthen the company's long-term competitive position and future product portfolio.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-phase-1-aln-4285-data-highlights-expanding-rnai-plat/amp

Trending Today

Solana ($SOL) Crypto Forecast: Up 6.6% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.9% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 5.2% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.3% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Up 5.2% Today

TE Connectivity Ltd. New Switzerland Registered Shares ($TEL) Stock Forecast: Down 3.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Up 4.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 6.0% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.0% Today

Moderna Inc. Price History

11.01.2026 - MRNA Stock was down 9.3%

• A recent FDA decision on Moderna's flu vaccine application is seen as a setback for the company's vaccine pipeline, potentially influencing the bearish movement in the stock.
• However, the acceptance of mRNA-1010 for review in various regions such as the EU, Canada, and Australia may offer some comfort to investors, mitigating the overall impact on Moderna's financial prospects.
• The company's new five-year vaccine agreement with the Mexican government has the potential to counterbalance the negative sentiment from the FDA decision, indicating a strategic move for revenue growth and expansion into new markets.
• The market's response to Moderna's bearish trend today may reflect the varied reports on its vaccine developments and collaborations, with investors keen on monitoring the firm's regulatory advancements and commercial ventures in the future.

20.01.2026 - MRNA Stock was up 8.3%

• The positive momentum in MRK stock could be linked to an upgraded Buy rating from Deutsche Bank with an increased price target. This optimistic forecast on the company's growth prospects, disregarding concerns about the Keytruda patent cliff, likely bolstered investor confidence.
• Furthermore, the FDA's approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication affirmed Merck's market position, underscoring its dedication to developing groundbreaking treatments.
• Ongoing patent disputes and legal conflicts in the biotech sector, like BioNTech's lawsuit against Moderna for patent infringement regarding COVID shots, may have impacted market sentiment towards established players such as Merck, potentially generating heightened interest and investment in the company's stock.

23.01.2026 - MRNA Stock was up 6.0%

• Moderna experienced a strong bullish movement today due to multiple factors:
• Gilead Sciences' acquisition of Arcellx, focusing on CAR T-cell therapy, brought positive attention to the biotech sector and potentially increased investor confidence in similar companies like Moderna.
• The FDA's decision to review Moderna's mRNA flu vaccine and the initiation of the review for its investigational seasonal influenza vaccine submission (mRNA-1010) signaled progress and potential future revenue streams for the company.
• Despite facing legal challenges related to patent infringement and mixed financial results, including declining revenue, the positive developments with FDA reviews and vaccine submissions outweighed the concerns for investors.
• Telemark Asset Management LLC's significant acquisition of Moderna shares also indicated confidence in the company's future prospects, contributing to the bullish movement.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

19.01.2026 - MRNA Stock was up 5.6%

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

18.01.2026 - MRNA Stock was up 9.5%

• Moderna faced setbacks in a patent dispute with Arbutus Biopharma, but the market remained bullish, indicating that investors are focusing more on the company's overall potential and developments in its vaccine pipeline.
• The FDA's decision to review Moderna's mRNA flu shot application, along with the positive results from the mid-stage trial of their combo flu/COVID vaccine, likely contributed to the bullish movement of the stock.
• Despite the ongoing legal challenges and regulatory hurdles, Moderna's innovative approach to vaccine development and the promising results of its trials seem to have instilled confidence in investors, driving the stock price up.

18.01.2026 - MRNA Stock was up 5.5%

• Optimism among investors was ignited by the FDA's decision to reassess Moderna's mRNA flu shot application after an initial rejection, potentially creating a new revenue source for the company.
• Despite uncertainties stemming from setbacks in the patent dispute with Arbutus Biopharma, investor focus on the flu vaccine review seemed to outweigh these concerns.
• Strong results from Moderna's combination flu/COVID vaccine trial further solidified investor confidence in the company's capabilities and future outlook, driving the bullish movement in stock price.
• Overall, market response to the FDA's review of Moderna's flu shot and encouraging vaccine trial outcomes indicates investor optimism about the company's ongoing success and innovation within the healthcare sector.

12.01.2026 - MRNA Stock was up 8.6%

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

02.02.2026 - MRNA Stock was up 5.2%

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

13.01.2026 - MRNA Stock was up 7.3%

• Moderna experienced a strong bullish movement today as its sales beat expectations, driven by robust demand for its Covid-19 vaccine, which declined less than anticipated.
• The positive sales performance indicates that Moderna continues to play a significant role in the global vaccination efforts, contributing to its revenue growth.
• The market's reaction to Moderna's sales beat showcases investor confidence in the company's ability to navigate through changing demand dynamics for Covid-19 vaccines.
• The news of Moderna's sales exceeding estimates likely fueled investor optimism and contributed to the bullish movement in the stock price.

13.01.2026 - MRNA Stock was up 6.7%

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.